Introduction. Among the population of Central and Eastern Europe, hyperuricemia (HU) prevalence is 28 % in female and 23 % in male. In 2018, European Society of Hypertension has officially included HU to the independent risk factors for AH.
Objective: to integrate literature and own data that reflect contemporary views on the role of hyperuricemia in the progression of arterial hypertension and study the early effects of hyperuricemia on endothelial dysfunction.
Materials and methods. Total of 382 persons were analyzed to evaluate the prevalence of hyperuricemia in Sumy region. To study the early effects of hyperuricemia on endothelial dysfunction in normotensive patients two groups were formed: 31 patients with UA < 400 μmol/l (1st group) and 29 patients with UA > 400 μmol/l (2nd group). The groups were comparable in age and sex.
Test with reactive hyperemia for estimation of endothelium-dependent vasodilation (EDVD) was performed using the ultrasound system SonoScape S6. Increasing of brachial artery diameter less than 10 % during the test with reactive hyperemia was considered as a criterion of endothelial dysfunction.
Results: the prevalence of hyperuricemia in Sumy region is about 42 % for normotensive patients and 51 % – in hypertension patients from total cohort 382. Daily BP monitoring demonstrated daytime systolic blood pressure (DaySBP) 118 mmHg and daytime diastolic blood pressure (DayDBP) 72 mmHg in the 1st group; and in the 2nd group these were: DaySBP 130 mmHg, DayDBP 80 mmHg (р < 0.05).
Analysis of baseline levels of EDVD shows significant difference between groups: 12.9 % and 9.6 % in the 1st group and 2nd group, respectively (р < 0.05). The average UA level in the 1st group was 328 ± 24 μmol/l; in the 2nd group – 469 ± 34 μmol/l. The negative correlation was obtained between the level of UA and EDVD: -0.32 in the 1st group and -0.48 in the 2nd group (p < 0.05).
Conclusion. Study results demonstrated high prevalence of HU both in hypertensive and normotensive patients. Statistically significant relationship between endothelium-dependent vasodilation and uric acid levels in patients was established.
2. Ali N, Perveen R, Rahman S, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. PLoS One. 2018;13(11):e0206850. doi:10.1371/journal.pone.0206850
3. Cui, L, Meng L, Wang G, Yuan X, Li Z, Mu R, & Wu S. Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. Modern Rheumatology. 2017; 27(6):1066–1071. doi:10.1080/14397595.2017.1300117
4. Chen‐Xu M, Yokose C, Rai SK, Pillinger MH and Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007‐2016. Arthritis Rheumatol. 2019; doi:10.1002/art.40807
5. Williams B, Mancia G, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Managementof Arterial Hypertension. J Hypertens. 2018;36(12):2284-2309. doi: 10.1097/HJH.0000000000001961
6. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram SLeM, Ishimoto T, Sautin YY, Lanaspa MA. Sugar uric acid and the etiology of diabetes and obesity. Diabetes. 2013; 62(10):3307-15. doi: 10.2337/db12-1814
7. Battelli mg, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2014;1842, (9):1502-1517/ doi.org/10.1016/j.bbadis.2014.05.022
8. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016;11(1):54-59. doi: 10.15420/ecr.2016:4:2
9. Pinelli M, Bindi M, Moroni F, M. Castiglioni Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure. Acta Cardiol 2008;63(2):191-5.
10. Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: a mechanism for uric acid-induced endothelial dysfunction. Int J Mol Med. 2016;37(4):989-97. doi: 10.3892/ijmm
11. Otani N, Toyoda S, Sakuma M, Hayashi K, Ouchi M, Fujita T, Inoue T. Effects of uric acid on vascular endothelial function from bedside to bench. Hypertens. Res. 2018;41(11):923-931. doi: 10.1038/s41440-018-0095-4
12. Mishima M, Hamada T, Maharani N, et al. Effects of uric acid on the NO production of HUVECs and its restoration by urate lowering agents. Drug Res (Stuttg). 2016;66(5):270-4. doi: 10.1055/s-0035-1569405
13. Ofori SN, Odia OJ. Serum uric acid and target organ damage in essential hypertension. Vasc Health Risk Manag. 2014;(10):253-61. doi:10.2147/VHRM.S61363
14. Scheepers LE, Boonen JM. A uric acid and blood pressure: exploring the role of uric acid production in The Maastricht Study. J Hypertens. 2017;35(10):1968-1975. doi: 10.1097/HJH.0000000000001417
15. Kansui Y, Matsumura K, Morinaga Y, Inoue M, Kiyohara K, Ohta Y, Goto K, Ohtsubo T, Ooboshi H, Kitazono T. Impact of serum uric acid on incident hypertension in a worksite population of Japanese men. J Hypertens. 2018;36(7):1499-1505.
16. Kuwabara M. Hyperuricemia Cardiovascular Disease and Hypertension. Pulse (Basel). 2016;3(3-4):242-52. doi:10.1159/000443769
17. Turak O et al. Serum Uric Acid, Inflammation and Nondipping Circadian Pattern in Essential Hypertension. The Journal of Clinical Hypertension. 2013;15(1):7-13. doi: 10.1111/jch.12026
18. Buzas R, Tautu OF, Dorobantu M, Ivan V, Lighezan D Serum uric acid and arterial hypertension - Data from Sephar III survey. PLoS ONE. 2018;13(7). Retrieved from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199865
19. Yokokawa H, Fukuda H, Suzuki A ET al.. Association between serum uric acid levels hyperuricemia and hypertension among 85286 Japanese Workers. Clin Hypertens (Greenwich) 2016;18(1):53-9. doi: 10.1111/jch.12627
20. Zheng R, Yang T, Chen Q, Chen C, & Mao Y. Serum uric acid concentrations can predict hypertension: a longitudinal population-based epidemiological study. Hormone and Metabolic Research. 2017;49(11):873–879. doi:10.1055/s-0043-119129
21. Orlando A, Cazzaniga E, Giussani M, Palestini P, Genovesi S. Hypertension in children: role of obesity, simple carbohydrates and uric acid. Front Public Health. 2018;3(6):129.
22. Kuwabara M, Hisatome I, Niwa K et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;(71):78–86. doi: 10.1161/HYPERTENSIONAHA.117.10370.
23. Wang J, Chen J, Li Y, Wang L, Huang H et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies PLoS ONE. 2014; 9 (12):114-259.
24. Mazza A, Lenti S, Schiavon L et al. Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population. Biomed Pharmacother. 2016;(86):590-594. doi: 10.1016/j.biopha.2016.11.104
25. Cicero AFG. et al. High serum uric acid is associated to poorly controlled, blood pressure and higher arterial stiffness in hypertensive subjects. European Journal of Internal Medicine. 2016;(37):38-42. doi: https://doi.org/10.1016/j.ejim.2016.07.026
26. Leiba A, Vinker S, Dinour D, Holtzman EJ, Shani M. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens. 2016, 9(8):600-609.
27. Kuwabara M et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan International. Journal of Cardiology. 2018;261:183–188 doi:https://doi.org/10.1016/j.ijcard. 2018.03.045
28. Cicero AFG, Fogacci F, Giovannini M. Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. Journal of Hypertension. 2018;37(4):728–731. doi: 10.1097/HJH.0000000000001927
29. Sun HL, Pei D, Lue KH, Chen YL. Uric acid levels can predict metabolic syndrome and hypertension in adolescents: a 10-year longitudinal study. PLoS ONE. 2015;10(11):e0143786. doi: 10.1371/journal.pone.0143786
30. Wei F, Sun N, Cai C, Feng S, Tian J, Shi W et al. Associations between serum uric acid and the incidence of hypertension: a Chinese senior dynamic cohort study. J Transl Med. 2016;14(1):110-116.
31. Ramirez AJ, Christen AI, Sanchez RA. Serum uric acid elevation is associated to arterial stiffness in hypertensive patients with metabolic disturbances. Current Hypertension Reviews. 2018;14(2):154-160. doi: 10.2174/ 1573402114666180413143312
32. Tomiyama H, Shiina K, Vlachopoulos et al. Involvement of arterial stiffness and inflammation in hyperuricemia-related development of hypertension. Hypertension. 2018;72(3):739-745. doi: 10.1161/HYPERTENSIONAHA.118.11390
33. Viazzi F, Garneri D, Leoncini G, et al. Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. Nutr Metab Cardiovasc Dis 2014;24(8):921-7. doi: 10.1016/j.numecd.2014.01.018
34. Tsai C, Lin S, Kuo C, Huang C. Serum Uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017;12(1):e0170393. doi: 10.1371/journal.pone.0170393
35. Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, Pilot Study. Clin Drug Investig. 2015;35(12):823-831.
36. Luo Q, Xia X, Li B, Lin Z, Yu X, Huang F. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2019;20(1):18. doi:10.1186/s12882-018-1143-7.
37. Komendarek-Kowalska M. The assessment of renal function in patients with newly diagnosed hypertension - the role of hyperuricemia as a risk factor for chronic kidney disease - preliminary study. Pol Merkur Lekarski. 2017;42(251):193-196.
38. Chen Y., Xu B, Sun W, Sun J, Wang T, Xu Y, et al. Impact of the serum uric acid level on subclinical atherosclerosis in middle-aged and elderly Chinese. J Atheroscler Thromb. 2015;22(8):823-832.
39. Kuwabara M, Sato Y, Kanbay M, & Johnson RJ. Uric Acid and Left Ventricular Hypertrophy: A Potentially New Modifiable Target? American Journal of Hypertension. 2017;30(3):229-231. doi: 10.1093/ajh/hpw195
40. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;266(6):558-570.
41. Gu J, Fan YQ, Zhang HL, Zhang JF, Wang CQ. Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. J Clin Hypertens. 2018;20:560–567. https://doi.org/10.1111/jch.13210
42. Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, Pilot Study. Clin Drug Investig. 2015;35(12):823-831.
43. Gunawardhana L, McLean L, Punzi HA et al. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study. J Am Heart Assoc.2017;6(11):66-83. doi:10.1161/JAHA.117.006683
44. Doehner W, Jankowska EA, Springer J, Lainscak M, Anker SD. Uric acid and xanthine oxidase in heart failure – emerging data and therapeutic implications. Int J Cardiol. 2016;15(213):15-19.